Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states.
about
Correlating corneal arcus with atherosclerosis in familial hypercholesterolemiaGenetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease riskClinical management of children and young adults with heterozygous familial hypercholesterolaemia in the UKCost effectiveness analysis of different approaches of screening for familial hypercholesterolaemiaReductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry studyRisk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register GroupSubjects with molecularly defined familial hypercholesterolemia or familial defective apoB-100 are not being adequately treatedUse of targeted exome sequencing as a diagnostic tool for Familial HypercholesterolaemiaRadiation and Circulatory DiseaseTwo years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal.Novel low density lipoprotein receptor variant linked to early onset acute myocardial infarction in a patient with familial hypercholesterolaemia.Genetic and environmental variation in serum lipoproteins in relation to coronary heart disease.Monogenic disorders.Six DNA polymorphisms in the low density lipoprotein receptor gene: their genetic relationship and an example of their use for identifying affected relatives of patients with familial hypercholesterolaemia.Enhanced status of inflammation and endothelial activation in subjects with familial hypercholesterolaemia and their related unaffected family members: a case control studyScreening for familial hypercholesterolaemia in childhood: Avon Longitudinal Study of Parents and Children (ALSPAC)Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trials.Familial hypercholesterolemia: A reviewEditorial: Early prevention of atherosclerosis.Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutationsUsing body mass index data in the electronic health record to calculate cardiovascular riskImproved survival of patients with homozygous familial hypercholesterolaemia treated with plasma exchange.Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease.Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia.Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood.Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia.Familial hypercholesterolemia: current treatment and advances in management.Contrasting patterns of coronary atherosclerosis in normocholesterolaemic smokers and patients with familial hypercholesterolaemia.Can drug therapy alter the natural course of peripheral vascular disease?: a review.Lipoprotein measurements--a necessity for precise assessment of risk in children from high-risk familiesScreening for familial hyper-beta-lipoproteinaemia in children in hospital.Familial hypercholesterolemia: the lipids or the genes?Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART)Serum lipids and lipoproteins in children from families with early coronary heart diseaseUse of cholestyramine in treatment of children with familial hypercholesterolaemia.Gonadal hormones and triglycerides.Cholesterol screening and life assurance.Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia.Plasma lipoprotein levels and the prevalence of hyperlipoproteinemia in a Canadian working population.Combination treatment with cholestyramine and bezafibrate for heterozygous familial hypercholesterolaemia
P2860
Q21093276-CF2C48DD-82A4-4299-B6E9-C66E971C223BQ24322584-1B104250-BDA3-40FA-9717-FD9E30085CF9Q24522271-057B944A-21B5-4E2B-A069-9D5825106753Q24528552-20F14E92-181C-466E-ADD4-BBD3E6E8E4ABQ24645376-8F052179-C3B8-4A1C-972D-326FCBE22AB6Q24675141-75C62FEF-86D5-48D7-AC3E-C2F2D04D1EC6Q28477200-1D05230B-426A-4B61-8B1D-D1F2D6EDD115Q28716905-A966E0B2-A763-4902-B70A-8ABBCAED1F7AQ29248999-051AA138-0909-47A5-B14B-36A222E328ADQ33532632-F123AF69-2371-48B5-B296-FB2C89A84F10Q33576564-609B8F37-630D-4A92-BD46-CF188D43A6FAQ33584798-0113DA8F-8BD5-4130-AE37-1CA22AA46379Q33587779-5C4E13F4-F643-473B-AC78-BAF0D3ACB7DCQ33595177-5A8D0C3C-50E2-4535-8AE4-EE4BD66179BEQ33601191-EE211883-0717-4087-9BA7-A2E6E0745BB6Q33630769-0D737067-ADE6-462C-884D-425DC9558012Q33670893-F1122C71-113D-445F-8F42-788E5C5FA6E9Q33803782-03182970-4B4E-4ABF-9F1F-1FBEC183FE67Q33823262-FCBC6369-5D27-438D-B62C-F84DAB36DC8BQ33956413-0E745579-3E1E-44AC-B285-2AA7253FE344Q34198287-DFB074ED-7E12-4413-A840-28FDA5997452Q34492190-362CA273-7A1A-414E-9959-BF5EF99A6E9AQ34499298-D4A01B9C-ED37-44DA-B6F3-504354935827Q34506656-1ED30C1E-9C5A-428B-AB5B-5F986A126BBAQ34516873-C7BC2623-7E24-4445-BEC5-FEB48DC1FF0DQ34621428-8CF15E77-5CD5-4D0F-8836-D9203522CD56Q34769059-50D9802E-C416-4C1B-BEB4-9642A1E39617Q34785390-C0AE7980-893B-4C6B-A6D1-561663E3B939Q34981446-58DFFC0F-4053-4CE6-9148-D50FD623D49BQ34988473-8E86C525-8B81-42EC-B390-9734B25AA2E0Q34989219-E76F71B5-48E0-46A0-ADBF-EFF5FF5EB5B2Q35014525-B2EA2EED-BF4F-4CBB-8518-A98BECA6F900Q35121832-51F59410-6826-4B7E-ADC0-400D359C0CBFQ35150068-6146CF6D-9A9A-4848-95A6-4C7B72C9C5CAQ35150378-C378ABE3-B470-44B8-B8E8-5938F74B6B35Q35154507-E305C0A2-65A9-47F5-98A8-D98916E02366Q35178683-87891EE0-E296-4D3C-BFA9-E524ED15A576Q35583268-959C735C-4933-4086-9BAC-409204DC6B6FQ35644647-D6D747C2-FB8C-4C68-AE80-EE9E32F377A7Q35702516-877761F7-BF28-4C6A-8558-92C168433865
P2860
Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states.
description
1969 nî lūn-bûn
@nan
1969年の論文
@ja
1969年学术文章
@wuu
1969年学术文章
@zh
1969年学术文章
@zh-cn
1969年学术文章
@zh-hans
1969年学术文章
@zh-my
1969年学术文章
@zh-sg
1969年學術文章
@yue
1969年學術文章
@zh-hant
name
Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states.
@en
Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states.
@nl
type
label
Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states.
@en
Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states.
@nl
prefLabel
Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states.
@en
Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states.
@nl
P1433
P1476
Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states.
@en
P2093
P304
P356
10.1016/S0140-6736(69)90930-1
P407
P577
1969-12-01T00:00:00Z